Full-Time

Director, Commercial Insights and Analytics

Olema Oncology

Olema Oncology

51-200 employees

Clinical-stage biopharma targeting ER-positive breast cancer

Compensation Overview

$230k - $250k/yr

+ Equity + Bonus

Boston, MA, USA

Hybrid

The role is based in the San Francisco or Boston office and requires approximately 20% travel.

Bachelor's, Master's, MBA, PhD

Category
Business & Strategy (1)
Required Skills
Market Research
Quantitative Research
Data Science
Forecasting
Data Analysis

Get referred to Olema Oncology

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • Strong understanding of biopharmaceutical commercialization in oncology markets, including patient journeys, customer behavior, treatment dynamics, market access, and launch performance.
  • Deep expertise in analytical methodologies sufficient to frame business questions, interpret outputs, challenge assumptions, and partner effectively with technical and analytical colleagues.
  • At least 10 years of progressive responsibility in biopharmaceutical market research, insights, forecasting, competitive intelligence, commercial strategy, management consulting, or related disciplines.
  • A forward-looking approach to insights generation, including the use of artificial intelligence-enabled tools, automation, and modern research methodologies.
  • A track record of supporting late-stage assets, launch planning, and in-market brands.
  • Strong capability in patient-based commercial forecasting, scenario analysis, and market assessment.
  • The ability to integrate primary research, competitive intelligence, secondary analyses, epidemiology, and other evidence into a coherent strategic perspective.
  • The ability to present recommendations and influence decisions with senior executives and cross-functional leadership teams.
  • Successful management of agencies, consultants, and other external partners.
Responsibilities
  • Build and lead an integrated insights capability supporting commercial strategy, launch readiness, and lifecycle planning.
  • Serve as a strategic thought partner to Commercial leadership and cross-functional stakeholders by bringing together primary market research, forecasting, and competitive intelligence to address business questions.
  • Develop a deep understanding of customers, patients, and competitors and translate it into implications and recommendations for the business.
  • Ensure that the organization has the right insights at the right time to inform product strategy, launch planning, customer engagement, market development, and investment prioritization.
  • Frame ambiguous business questions, design research and analytical approaches, pressure-test assumptions, and translate disparate information into executive-ready recommendations.
  • Serve as the lead insights thought partner to Commercial leadership by identifying critical questions, risks, and opportunities that should inform strategy and execution.
  • Lead an integrated insights planning process and synthesize primary research, secondary data, competitive intelligence, epidemiology, and market developments into a cohesive market perspective.
  • Translate insights into implications and recommendations and identify priority knowledge gaps and appropriate approaches to address them.
  • Own the primary market research strategy and annual research plan supporting the portfolio and commercialization priorities.
  • Design and execute qualitative and quantitative research into unmet needs, treatment decisions, product perceptions, adoption barriers, and market opportunities.
  • Lead the development, refinement, and governance of patient-based commercial forecasts for the late-stage portfolio, incorporating epidemiology, patient flow, market research, competitive dynamics, access assumptions, analogs, and clinical and regulatory events.
  • Develop and communicate scenario-based forecasts for long-range planning, portfolio prioritization, lifecycle strategy, and business development assessments.
  • Lead commercial competitive intelligence for priority disease areas by maintaining an integrated view of competitors, emerging mechanisms, and evolving treatment paradigms.
  • Lead synthesis around major congresses, data readouts, regulatory events, and other high-impact milestones.
  • Define the strategic measurement framework for launch, including key performance indicators and leading indicators spanning patient dynamics, customer engagement, access, adoption, and market evolution.
  • Partner with analytical colleagues to ensure required data, reporting, and measurement capabilities are in place.
  • Lead interpretation of launch performance by integrating quantitative signals with primary research, field insights, and competitive context to identify drivers and recommended actions.
Desired Qualifications
  • An MBA, PhD, or another relevant advanced degree is preferred.

Olema Oncology develops targeted therapies for women’s cancers, with a focus on ER+/HER2- breast cancer. Its lead candidate palazestrant (OP-1250) is a dual CERAN/SERD that blocks estrogen signaling and promotes estrogen receptor degradation. The company is running a Phase 3 trial of palazestrant in combination with CDK4/6 inhibitors and has a collaboration with Novartis to test the therapy with ribociclib and everolimus. A second program, a KAT6 inhibitor, is in preclinical development, targeting epigenetic regulation.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2007

Get referred to Olema Oncology

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • OPERA-01 completed enrollment August 10, 2026; topline data arrive first quarter 2027.
  • Bayer deal started May 26, 2026, funding OP-3136 combination work without Olema paying drug supply.
  • Jason O'Byrne joined August 13, 2026, strengthening finance after Shane Kovacs's January departure.

What critics are saying

  • OPERA-01 slipped from fall 2026 to first quarter 2027, postponing any filing until 2028.
  • Second-quarter 2026 net loss hit $63.2 million; cash fell to $461.1 million.
  • Ra Capital, Jennison, and Polar exited in Q2 2026, signaling late-stage skepticism.

What makes Olema Oncology unique

  • Palazestrant blocks wild-type and mutant ER, separating Olema from weaker SERDs.
  • OP-3136 adds a KAT6 axis, giving Olema a second endocrine-resistance lever.
  • Novartis and Bayer collaborations validate partner interest around Olema's combination strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Paid Vacation

Flexible Work Hours

Hybrid Work Options

Stock Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Development Training Programs

Tuition Reimbursement

Professional Certification Support

Adoption Assistance

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Relocation Assistance

Bonus

Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Associated Press
Sep 2nd, 2026
Olema Oncology grants CFO 650,000 stock options at $10.56 per share

Olema Oncology granted Jason V. O'Byrne, its new chief financial officer, stock options to purchase 650,000 shares of the company's common stock as an employment inducement award. The grant, effective 1 September 2026, has an exercise price of $10.56 per share, matching Nasdaq's last reported sale price on that date. The options vest over four years, with 25% vesting on 11 August 2027 and the remainder vesting in 36 equal monthly instalments over the following three years, subject to continuous employment. O'Byrne's appointment as CFO became effective 11 August 2026. The award was approved by Olema's Compensation Committee and granted under the company's 2022 Inducement Plan. Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer.

Quiver Quantitative
Sep 2nd, 2026
Olema Pharmaceuticals grants inducement stock options to newly appointed CFO Jason V. O'Byrne.

Olema Pharmaceuticals grants inducement stock options to newly appointed CFO Jason V. O'Byrne. Posted: 1 day, 9 hours ago / Sept. 2, 2026 8:40 p.m. UTC Olema Pharmaceuticals appointed Jason V. O'Byrne as CFO, granting him 650,000 stock options effective September 1, 2026. Quiver AI summary. Olema Pharmaceuticals, Inc. has announced the appointment of Jason V. O'Byrne as Chief Financial Officer, effective August 11, 2026. To incentivize his role, the company granted him an employment inducement award that includes stock options to purchase 650,000 shares at an exercise price of $10.56 per share, based on the latest Nasdaq reporting. The stock options will vest over four years, with an initial 25 percent vesting on August 11, 2027, followed by monthly vesting. This grant aligns with Nasdaq regulations and is part of Olema's 2022 Inducement Plan. Olema is focused on developing innovative treatments for breast cancer, including the lead candidate palazestrant, currently in Phase 3 trials, and OP-3136, which is in Phase 1 trials. The company operates out of San Francisco and Cambridge, Massachusetts. Potential positives. * Olema Pharmaceuticals appointed Jason V. O'Byrne as Chief Financial Officer, indicating a strategic move to strengthen the company's financial leadership. * The company granted an employment inducement award of 650,000 stock options to Mr. O'Byrne, demonstrating confidence in his capabilities and aligning his interests with shareholders. * The stock options are set at an exercise price equal to the last reported sale price, encouraging performance that aligns with market expectations. * Olema's ongoing commitment to developing innovative therapies for breast cancer, including their lead product candidate, palazestrant, underlines the company's focus on advancing significant medical solutions. Potential negatives. * Granting a significant stock option package (650,000 shares) to the new CFO may raise concerns among investors regarding the company's compensation practices, especially at a time when the company is still in the clinical stage and may not yet be financially stable. * The substantial vesting period for the stock options (four years) could be viewed negatively, as it may imply the need for long-term incentives to retain leadership amidst ongoing challenges in clinical trials and commercialization efforts. * The mention of the employment inducement award might distract from Olema's clinical updates and progress on drug development, potentially raising concerns about prioritization and resource allocation within the company. Faq. Who is Olema Pharmaceuticals? Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and beyond. What recent appointment did Olema announce? Olema announced the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026. What is the stock option grant for Jason O'Byrne? The stock option grant consists of 650,000 shares with an exercise price of $10.56 per share. How does the stock option vest? The stock options vest over four years, with 25% vesting on August 11, 2027, and the remainder in monthly installments. What are Olema's lead product candidates? Olema's lead product candidates include palazestrant (OP-1250) and OP-3136, targeting endocrine-driven cancers. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here. EARLY ACCESS Receive OLMA Data Alerts Real-time alerts on filings, insider trades, and market signals - before everyone else. $OLMA insider trading activity. $OLMA insiders have traded $OLMA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales. * SHAWNTE MITCHELL (CHIEF LEGAL OFFICER) has made 0 purchases and 2 sales selling 25,000 shares for an estimated $606,352. * CYRUS HARMON has made 0 purchases and 2 sales selling 25,000 shares for an estimated $291,162. To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint. $OLMA hedge fund activity. We have seen 94 institutional investors add shares of $OLMA stock to their portfolio, and 131 decrease their positions in their most recent quarter. Here are some of the largest recent moves: * RA CAPITAL MANAGEMENT, L.P. removed 2,600,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $32,526,000 * JENNISON ASSOCIATES LLC removed 1,822,123 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,794,758 * FMR LLC added 1,756,217 shares (+16.9%) to their portfolio in Q2 2026, for an estimated $21,970,274 * CORMORANT ASSET MANAGEMENT, LP removed 1,750,000 shares (-44.9%) from their portfolio in Q2 2026, for an estimated $21,892,500 * POLAR CAPITAL HOLDINGS PLC removed 1,602,970 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $20,053,154 * DEEP TRACK CAPITAL, LP added 1,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $18,765,000 * FRANKLIN RESOURCES INC added 1,130,629 shares (+92.8%) to their portfolio in Q2 2026, for an estimated $14,144,168 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint. $OLMA price targets. Multiple analysts have issued price targets for $OLMA recently. We have seen 6 analysts offer price targets for $OLMA in the last 6 months, with a median target of $39.0. Here are some recent targets: * Brad Canino from Guggenheim set a target price of $35.0 on 05/13/2026 * Dennis Ding from Jefferies set a target price of $40.0 on 03/19/2026 * Richard Law from Goldman Sachs set a target price of $27.0 on 03/18/2026 * Anupam Rama from JP Morgan set a target price of $58.0 on 03/18/2026 * Yigal Nochomovitz from Citigroup set a target price of $62.0 on 03/17/2026 * Emily Bodnar from HC Wainwright & Co. set a target price of $38.0 on 03/09/2026 Full release. SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O'Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company's common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 1, 2026. The award was approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan. The stock options vest over four years, with 25 percent vesting on August 11, 2027 and the remainder vesting in 36 equal monthly installments over the following three years, subject to continuous employment as of such vesting dates. Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com. Media and Investor Relations Contact Courtney O'Konek Vice President, Corporate Communications Olema Oncology [email protected]

BioCentury
Aug 13th, 2026
Vir CFO O'Byrne joining Olema.

Vir CFO O'Byrne joining Olema. Plus: changes at zenas, kamada and more. By BioCentury Staff August 13, 2026 5:12 PM PDT Jason O'Byrne has joined breast cancer company Olema Pharmaceuticals Inc. (NASDAQ:OLMA) as CFO from Vir Biotechnology Inc. (NASDAQ:VIR), where he held the same role. O'Byrne was also CFO of Caribou Biosciences Inc. (NASDAQ:CRBU) and SVP of Finance at Astellas Pharma Inc. (Tokyo:4503)... Just want immediate access to this one article? Purchase it now.

LOPJLB
Aug 12th, 2026
Olema Pharmaceuticals (OLMA) - pivotal breast-cancer data delay triggers **SELL** signal amid crisis regime.

Olema Pharmaceuticals (OLMA) - pivotal breast-cancer data delay triggers **SELL** signal amid crisis regime. OLMA SELL CRISIS sell flip OLMA Olema Pharmaceuticals, Inc. $10.13 -15.16% LOPJLB.COM Olema Pharmaceuticals closed at $10.43, down 12.65 % on the 2026-08-11 session (Tuesday, US session). The steep decline follows the company's announcement that pivotal Phase 2/3 data for its lead breast-cancer candidate, OP-1250, will not be available until 2027, a timeline shift that has intensified the firm's already fragile financial profile. News & catalysts. * Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 - Benzinga, 2026-08-11 14:27:24. The release explained that additional enrollment and a stronger statistical powering are required, pushing any regulatory filing to 2028. * Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA(R)(darolutamide) in Metastatic Castration-Resistant Prostate Cancer - GlobeNewswire, 2026-05-26 07:00:00. The partnership expands Olema's pipeline beyond women's oncology but does not offset near-term cash-burn. * Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - GlobeNewswire, 2026-05-21 17:00:00. Early-stage safety and activity signals were presented, but the path to pivotal trials remains long. * Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript - Seeking Alpha, 2026-06-09 21:22:12. Executives highlighted OP-1250 as a potential first-in-class estrogen-receptor degrader and reiterated reliance on external financing through 2027. * Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire, 2026-08-04 16:30:00. * Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire, 2026-06-02 16:30:00. * Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire, 2026-05-19 16:30:00. These releases collectively shape the short-term outlook: the data delay is the dominant negative catalyst, while the Bayer collaboration and early Phase 1 read-outs provide modest upside narratives that are unlikely to offset the cash-burn pressure. Fundamentals and valuation. FINANCIAL HISTORY Live from OLMA · same charts as the stock page

The Registry
Jul 13th, 2026
Olema Oncology leases 38,000 SQFT at Kilroy oyster point, moving headquarters to south san francisco.

Olema Oncology leases 38,000 SQFT at Kilroy oyster point, moving headquarters to south san francisco. Clinical-stage breast cancer company Olema Oncology has committed to 38,176 square feet at Kilroy Re Partner content. 2026 northern california CRE rising stars. Signup for news and special announcements!